Artificial intelligence (AI) drug discovery firm Recursion Pharmaceuticals, has secured $121m in a series C funding round led by the Scottish Mortgage Investment Trust.

The Trust was joined by new investors Intermountain Ventures, Texas Tech University System, Regents of the University of Minnesota and certain angel investors.

Previous backers Lux Capital, Mubadala Ventures, Obvious Ventures, Two Sigma Ventures, Felicis Ventures, Menlo Ventures, Data Collective, AME Cloud Ventures, Epic Ventures, and CRV also participated in the fundraising.

Recursion uses AI with automated, experimental biology to discover and develop new therapies for rare diseases, inflammation, infectious disease, and immuno-oncology.

The company intends to use the latest proceeds to further develop its machine learning-based drug discovery platform. Besides, the funds will be utilised to accelerate the chemistry of a new chemical entity and predict safety pharmacology.

Recursion also plans to advance its own pre-clinical and clinical assets, including clinical-stage programmes targeting cerebral cavernous malformation and neurofibromatosis type 2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will also form industry alliances across immuno-oncology, oncology, ageing, and inflammation therapeutic areas, among others.

As part of the alliance formed with Takeda in 2017, Recursion was able to identify new therapeutic candidates for more than six diseases. Takeda exercised its option for drug candidates in a couple of rare diseases.

Recursion Pharmaceuticals CEO Chris Gibson said: “With these new resources, we will continue to drive toward a future in which drugs are developed, by people, with a new level of understanding about human biology that was simply not possible before machines.”

The company aims to build a map of human cellular biology in order to enable the quick discovery and development of new drugs for all diseases that can be modelled at the cellular level.

It has built a data set from automated screens for a variety of indications, such as infectious disease, cancer, inflammation, ageing, and diagnostics.